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Abstract
Toll-like receptors (TLRs) are the most essential pattern recognition receptors in 
mediating the effects of innate immunity. It plays a pivotal role in inducing immune 
response against a number of pathogens, various diseases conditions including 
pathogenesis of cancer. Inflammation is often associated with the development and 
progression of most of cancer, where TLRs interplay very crucial roles. Moreover, 
TLRs activation can impact the initiation, progression and treatment of cancer 
by modulating the inflammatory microenvironment. Rapidly growing number 
of  evidences related to  TLRs function and expression in cancer cells, suggests its 
critical association with chemoresistance and tumourigenesis. The current chapter 
describes the development of various agonist and antagosist for TLRs and their 
application in cancer therapeutics. The aim of this book chapter is to highlights 
basic features of TLRs, and its role in cancer progression. It also addresses, how a 
defect in the TLRs signaling pathway can contributes towards carcinogenesis and 
recent development of cancer therapeutics that target TLR signaling pathways.
Keywords: toll-like receptors (TLRs), cancer progression, TLR agonists, 
inflammation, signaling
1. Introduction to the toll-like receptors (TLRs)
TLRs are trans-membrane proteins receptors that trigger the signal transduc-
tion cascades upon binding with specific pathogen-associated molecular patterns 
(PAMPs) ligands, and earlier have been thought to be restricted to immune cells. 
TLRs play a key role in the innate immune system as well as subsequent induction 
of adaptive immune responses against microbial infection or tissue injury [1]. TLRs 
receptors triggers immune response against various invading pathogens by rec-
ognizing receptor specific to PAMPs, which is highly conserved and derived from 
potential pathogenic microorganism such as bacteria, viruses, fungi and parasites 
[2, 3]. The very well-known one such PAMPs is lipopolysaccharides (LPS) acts as 
ligands for TLRs, which is found on outer cell wall of gram negative bacteria [4]. 
Moreover, TLR receptors also recognize endogenous damage-associated molecu-
lar patterns (DAMPs), derived from injured host cells including necrotic cancer 
cells, dead or dying cells, or products released from cells in response to signals 
such as hypoxia and epithelial cells [5]. These PAMPs and DAMPs together help 
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in discriminating both self and non-self-danger signals [1, 2]. Specific TLR recep-
tors recognizes distinct microbial ligands i.e. lipopeptides, lipoteichoic acids, LPS, 
peptidoglycans, flagellins, viral and bacterial nucleic acids etc. [6]. These ligands 
binds to specific TLR receptors, initiate cascade pathway which plays important role 
in maintenance of cellular homeostasis, cell proliferation or apoptosis, cell differ-
entiation, as well as induction of inflammatory cytokines like interferons (IFNs), 
interleukins (IL2, IL6, IL8, IL12, IL16), and TNF-α to get rid of pathogens [3, 7].
Cancer develops when uncontrolled growth of abnormal cells occurs anywhere 
in a body and further metastasized to distant part of the body. In order to deepen 
our understanding of cancer biology, it is very important to address the factors 
that are involved in the tissue repair process, such as cytokines, chemokines, 
growth factors and TLR signaling, which are the key determinants of cancer 
progression [8, 9]. TLR signaling is known to activate nuclear factor-κB (NFκB) 
and mitogen-activated protein kinase (MAPK) pathways [10]. NF-κB in turn, 
regulates the expression of anti-apoptotic genes, and activation of the complement 
pathway depending upon type of ligands it sensed [11, 12]. Furthermore, TLRs are 
expressed not only on the surface of immune cells but also on cancerous cells [13]. 
In humans, TLRs (TLR1-TLR10) play very important role in diseases progression 
and the TLRs signaling have been well studied in various diseases including cancer 
[14]. The TLRs and their intracellular signaling components play very important 
role in the onset of inflammatory diseases [4]. Recent studies have revealed that 
chronic inflammation can increases the risk of cancer development and also 
promote its progression [14]. TLRs signaling also plays a crucial role in the develop-
ment of chemo-resistance; Michael et al., (2006) shows TLR4/MYD88 signaling 
promotes tumor growth and contributes to chemo-resistance against paclitaxel in 
ovarian cancer [9]. Moreover, a recent study delineates that high TLR7 and TLR8 
expression promotes chemo- resistance, leading to increases increased tumor cell 
proliferation in human pancreatic cancer [15]. However, the role of TLR signaling 
is still not completely understood in cancer progression; some studies suggest it  
has both pro-tumor as well as anti-tumor effects. To date, TLRs are documented to 
play supportive role for initiation, progression and metastatic potential of cancer 
[16, 17]. One the other hand, they are capable of maintaining antitumor environ-
ment by eliciting activation of anti-tumor mediators such as type I interferon 
[18]. This book chapter highlights the current understanding of role of TLRs and 
addresses a crucial link between  carcinogenesis and immune cells, TLRs signaling 
and antagonist.
2. TLRs genetics and regulation of signaling
TLRs were first described in Drosophila in 1984, and were later discovered in 
vertebrates including humans [1, 3]. Till date, 13 TLRs are discovered in mammals, 
and 10 are functional in humans [2]. Genes encoding human TLRs are located on 
chromosomes 1 (TLR5), 3 (TLR9), 4 (TLR1, TLR2, TLR3, TLR6 and TLR10), 9 
(TLR4) and X (TLR7 and TLR8) [1, 5]. TLR1–9 is conserved in both human and 
mice; however, mouse TLR10 is not functional because of a retrovirus insertion, 
and TLR11–13 has been lost from the human genome [8, 19, 20].
A number of genetic changes like single nucleotide polymorphisms (SNPs) 
within the TLR genes has been reported in humans which can influence receptor 
binding and function, that ultimately influences the risk for the inflammatory 
diseases as well as cancers [21]. Although there have been numerous studies report-
ing the impact of polymorphisms on TLR function and disease development, there 
is still a lot of contradiction in terms of outcomes [22].
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A recent report has shown that functional TLRs are expressed not only on 
immune cells, but also on cancer cells, thus implicating a role of TLRs in cancer 
biology. Overwhelming evidence supports that TLR signaling provides a micro-
environment that is necessary for tumor cells to proliferate and evade the immune 
response for further growth and migration [23]. The TLR family can be largely 
divided into 2 subgroups, extracellular and intracellular, depending on their cellular 
localization. TLR1, TLR2, TLR4, TLR5, TLR6, and TLR11 are located on the cell 
surface, while TLR3, TLR7, TLR8, and TLR9 are localized to the endosomal/ lyso-
somal compartment [10]. The subcellular localization of TLR4 is unique because it 
is localized to both plasma membrane as well as endosomal vesicles [24]. TLRs are 
type I transmembrane proteins that consist of three major domains: (1) a leucine 
rich extracellular domain, (2) a transmembrane domain, (3) A cytoplasmic TIR 
(Toll/Interleukin-1 Receptor) domain. The recognition of ligand by TLRs is medi-
ated by the extracellular domain that harbor a leucine rich repeat (LRR) composed 
of 19–25 tandem copies of the “xLxxLxLxx” motif [25]. TLR signaling was exten-
sively studied in the recent years. There are two important TLR pathways: one is 
dependent on myeloid differentiation factor 88 (MYD88) adaptor proteins and the 
other is independent of MYD88.
All TLRs except TLR3, which exclusively uses the TIR-domain-containing 
adapter-inducing interferon-β (TRIF) pathway, use MYD88 as the downstream 
adapter protein that activate the classical/canonical inflammatory signaling path-
way [26–29]. After activation with their specific ligands, TLRs recruit MYD88, 
leading to subsequent activation of three main transcription factors: interferon-
regulatory factors (IRF3, IRF5 and IRF7), NF-kB, MAPK and AP1 [21–25, 27–32]. 
Subsequently, it promote the transcription of cytokines such as TNF-α, IL-6 and 
IL-1, chemokines and interferons which are key mediators of inflammation [30]. 
Figure 1. 
Toll-like receptors (TLRs) signaling pathway:Toll-like receptors (TLRs) recognize different ligands and 
triggered innate immune responses. The activation of the TLR signaling pathway originates from the 
cytoplasmic TIR domain that associates with an adaptor, MYD88. IRAK is activated by phosphorylation and 
associates with TRAF6, leading to activation NF-κB. Activation of MYD88- independent pathways occurs 
via TRIF and TRAF activates interferon--regulatory factor (IRF). Then they promote the transcription of 
inflammation mediators: Cytokines, chemokines and interferons.
Cell Interaction - Molecular and Immunological Basis for Disease Management
4
Expression of cytokines also leads to maturation of dendritic cells and activation of 
B-cells and T-cells, which underlies the involvement of TLR in adaptive immunity 
[23]. TLR2 and TLR4 upon binding with their respective ligands form dimeric com-
plexes, followed by recruitment of 5 specific adapters, including 1) MYD88, 2) TIR 
domain containing adaptor protein (TIRAP)/MYD88 adaptor like (Mal), 3) TRIF, 
4) TRIF-related adaptor molecule (TRAM), and 5) sterile α and armadillo motif-
containing protein (SARM) [19, 33]. This response elicits the downstream responses 
like proliferation, invasion, inflammation and tumorigenesis etc. The schematic 
representation of the role of various TLRs signaling pathways is shown in Figure 1. 
This alternative/non-canonical pathway culminates in the activation of TRAF3 and 
interferon regulatory factor 3 (IRF3), which results in the secretion of type I IFNs, 
which are required for an effective antiviral response [31].
3. TLRs biology in the pathogenesis of cancer
In the host cell, TLRs are expressed either on cell membrane or in intracellular 
compartments (i.e. endosomes) [10]. TLRs belong to a family of pattern recogni-
tion receptors (PRRs) that are best-known for their role in host defense mechanism 
against a number of pathogens. Infection with potential microbial pathogens (bac-
teria, viruses, protozoa, and fungi) provokes innate and adaptive immune system 
[26]. In vertebrates, interactions between innate and adaptive immunity leads to 
highly efficient recognition and clearance of pathogens. Innate immune response 
elicits nonspecific activation of immune cells (neutrophils, monocytes, macro-
phages, dendritic cells (DCs), natural killer (NK) cells) and complements system 
[33, 34]. Inflammation is the immune system’s response to protect our body against 
any harmful stimuli like pathogens, cell damage and harmful/toxic compound. 
However, uncontrolled acute inflammation may become chronic; contributing to a 
variety of diseases including cancer [19]. In 1858, Rudolf Virchow noticed that the 
site of chronic inflammation is highly susceptible to cancer development [35]. He 
also hypothesized that chronic inflammation could promote the proliferation of 
cells and thus, the development of cancer. An association between the inflamma-
tion and development of cancer has long been appreciated [33]. In 2000, Hanahan 
and Weinberg proposed a model to define six hallmarks of cancer progression [36]. 
However, emerging evidence also reiterates the role of inflammation in cancer 
development. Various studies have shown a close link between chronic inflammation 
and cancer, such as long standing H.pylori infection and gastric cancer [37], chronic 
pancreatitis and pancreatic cancer, chronic bronchitis and lung cancer, human 
papillomavirus (HPVs) infection mediated cervical cancer [38], and chronic chole-
cystitis with gall bladder cancer [33]. Besides inflammatory response, TLR signaling 
has been shown to regulate apoptosis through the expression of anti-apoptotic 
proteins or inhibitors of apoptosis [39]. TLRs regulate variety of cellular responses 
which include the anti-apoptotic effect of NF-κB, a transcription factor commonly 
engaged in inflammatory conditions [12, 14]. Although this response can be initiated 
by several types of PRRs, and TLRs are the best-characterized key players. TLRs 
also regulate cell proliferation, apoptosis, invasion, and survival by recruiting more 
immune cells to enhance inflammation in the tumor microenvironment [40]. These 
tumor cells further release proangiogenic factors and growth factors, which enhance 
their resistance to cytotoxic lymphocyte attack, thereby leading to immune evasion. 
As mentioned earlier, TLRs function as double-edged swords, with both pro- and 
antitumor consequences. However, up-regulation of TLRs in tumor cells may 
directly or indirectly contribute to carcinogenesis in different organs. Engagement 
of TLRs on the surface of tumor cells with their ligands can activate subsequent 
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signaling cascades involving cytokine and chemokine production. Subsequently, 
these factors can promote tumor invasion, tumor cell survival ( apoptosis resistance), 
chemo-resistance, tumor progression and metastasis.
4. Molecular mechanism of TLRs in cancer progression
Overall, as discussed earlier, the activation of TLRs can promote as well as 
inhibit tumor growth and cancer progression, but the actual underlying molecular 
mechanism still remains elusive. TLRs are also involved in controlling many impor-
tant cellular processes like cell proliferation, survival, apoptosis, cell migration, 
metastasis and angiogenesis [16]. TLR signaling has been implicated in various 
autoimmune, chronic inflammation and inflammatory diseases. This situation 
creates a microenvironment that is rich in growth and survival factors, which leads 
to the development of various types of cancer [41]. High TLR expression has been 
reported in several cancer types including cancerous cell lines. It was known that 
TLR4 and TLR5 are over expressed in gastric epithelium infected with H. pylori 
as well as in precursor lesions [37, 42]. It is considered that TLRs enable cells to 
interact with H. pylori which can induce the expression of tumorigenic factors and 
may promote cancer development. TLR over–expression has also been found in 
colon cancer, hepatocellular carcinoma, ovarian and cervical cancers, breast and 
prostate cancers, lung cancer, melanoma and neuroblastoma [43]. TLR expres-
sion in cancer cells has been linked with cancer progression, evasion of immune 
surveillance, apoptosis and survival. Recent studies have shown high expression of 
TLR4 in lung cancer cells, which is linked with expression of immunosuppressive 
cytokines (TGFb), angiogenic factors VEGF and IL-8, and increased resistance to 
apoptosis [16, 42]. Cell proliferation and production of pro-inflammatory cytokines 
IL-6 and IL-8 can be significantly decreased by silencing of TLR4 expression in 
breast cancer cell line (MDA-MB-231) [44]. Other studies in ovarian cancer and cell 
lines has shown that TLR4 and NF-kB activation by LPS and paclitaxel respectively 
promotes production of IL-8, IL-6, VEGF and MCP-1 while TLR4 silencing lead to 
loss of resistance to Paclitaxel [45]. TLR2 mRNA expression was significantly higher 
in sporadic colorectal cancer cells than in noncancerous cells [45]. On the basis of 
above mentioned facts, we can deduce that various TLRs might trigger different 
signaling pathways in cancer initiation and progression [46].
A recent report found that activation of TLRs may induce cancerous cells to 
secrete a number of soluble factors, which play distinct roles in cancer develop-
ment. The role of TLRs in cancer progression needs to be further investigated, and 
in depth precise underlying mechanism must be elucidated for further development 
of TLR agonists as therapeutic agents.
5. TLRs modulation in cancer treatments
TLR agonists play an important role in activation of immune system, both  
innate and adaptive. In in vivo models, TLR antagonism have been shown to reduce 
tumor growth in treatment group, receiving combination of therapeutic agents, 
such chemotherapy drugs, monoclonal antibodies (mAb), subunit or DNA vaccines 
[47, 48]. The selection of TLR agonists has been premised on their ability to activate 
antigen-presenting cells (APCs), particularly DCs. The involvement of specific 
TLRs on cancer cells may impact tumor growth by various mechanisms, such as 
inducing apoptosis and potentiating the effects of chemotherapy [45]. Inhibition 
of TLRs can be achieved either by 1) Preventing the interaction between TLR 
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and respective binding partner and 2) By blocking the interaction between TLRs 
and respective adaptor protein. TLR inhibitors can be broadly classified into (i) 
Small molecule inhibitors, (ii) Antibodies, (iii) Oligonucleotides, and (iv) Lipid-A 
analogs. The following section illustrates the anticancer effects of inhibiting TLR 
signaling pathways on tumor growth and developments.
Small molecule inhibitors (SMI): These are synthetic or naturally derived 
small molecules with the ability to cross plasma membranes due to their small 
size and amphipathic nature. Interestingly, one of the most commonly used anti-
malarial drug chloroquine has been shown to possess inhibitory effects against 
endosomal TLR7/8/9 [49]. Inhibition of TLR7 and 9 by chloroquine inhibits the 
growth of hepatocellular carcinoma in both cellular in vitro models and mouse 
xenograft models via down regulation of p-Akt [50]. However due to their non spe-
cific mode of actions continuous efforts have been made to develop more efficient 
and specific derivatives of chloroquine as anti-cancer agents by targeting TLRs. 
One such derivative, CpG-52,363 has immunosuppressor functions but its role in 
cancer therapeutics is yet to be discovered [51]. SM934, a derivative of another 
anti-malarial drug artemensin can inhibit the proliferation and metastasis in breast 
cancer probably via inhibition of TLR signaling [52]. TAK-242 specifically inhibits 
TLR-4 by binding to cysteine 747 in the intracellular domain and consequently sup-
presses the progression of breast cancer [53]. Therapeutic role of SM934, another 
artemensin derivative has been well documented in inflammatory disease [54], but 
its role in cancer prevention is still need to be explored.
Antibodies: Various antibodies with therapeutic potential have been raised 
against TLRs to treat a wide spectrum of inflammatory diseases and cancer. 
Therapeutic role of OPN-305, the first fully humanized IgG against TLR2, against 
Myelodysplastic Syndromes (MDS) has been reported in different clinical trials 
[55]. Several antibodies have been developed beside OPN-305, like NI-0101and 
T2.5, but their role in cancer has not been determined yet [56].
Oligonucleotides: Specific nucleotide sequences are known to inhibit the func-
tion of endosomal TLRs by blocking their binding with respective ligands. These 
includes immunoregulatory DNA sequence (IRS) 661 (TLR7 specific), IRS-869 
(TLR9 specific) and IRS-954 (both TLR7 and 9 specific). Recent report suggest that 
TLR antagonism using immune modulator oligonucleotide-3100 (IMO-3100) can 
serve as a potential therapeutic for the management of pancreatic cancer associated 
cachexia [57].
Lipid A analogs: Eritoran, a syhnthetic analogue of lipid A from Rhodobacter 
sphaeroides, is known to inhibit TLR4 by binding to MD2 pocket and thereby 
preventing the interaction between TLR4 and lipid A. Bacterial LPS induced colon 
cancer can be prevented by the administration of Eritoran by mechanism involving 
inhibition TLR4 and induction of CD14/Src/PKCζ-mediated apoptosis [58].
It is important to mention here that TLR acts as double edged sword and its ago-
nism can also prevents the progression of cancer by activating the immune response 
against cancer cells. The following section describes TLR agonists which had shown 
the potential to prevent cancer progression.
Calmette–Guerin strain (BCG) a live-attenuated Mycobacterium bovis can 
activate TLR2, TLR4, and TLR9. The activation of TLR in urothelial cell carcinomas 
with BCG induced cell death and decreased proliferation as well as metaststais. 
The anti-cancer effects of BCG have been associated with increased production of 
cytotoxic NO in cell lines, as well as in patients [46]. These studies also emphasize 
the development of vaccination strategies that incorporate TLR ligands to stimulate 
immune responses and make cancerous cells specific targets for immune system 
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mediated death. In human colon cancer cells, TLR3 activation with Polyriboinosinic-
polyribocytidylic acid (Poly I:C) can induce apoptosis alone or when used in synergy 
with 5-fluorouracil or IFN-α [16]. Poly I:C is a synthetic analogue of viral dsRNA. 
The expression of TLR5 on cancer cells has been shown to revoke cell growth in cer-
tain types of cancer [16]. For instance, in breast cancer, when TLR5 is over–expres-
sion with flagellin inhibits tumor cell proliferation and downregulates expression of 
cyclin B1, cyclin D1 and cyclin E2 in a murine model [59].
Irradiation along with activation of TLR9 signaling pathway in human glioma 
cell line can decrease cell proliferation by arresting cell-cycle, which is mediated 
by NF-κB and nitric oxide (NO) [60]. This therapeutic effect could be used to 
sensitize the cancerous cells to the toxic effects of radiation treatment [61]. Also, 
CpG-island mediated activation of TLR9 in neuroblastoma cell has been revealed 
to decrease cell proliferation and increase caspase-dependent apoptosis and leads 
to an increased survival in tumor-bearing mice. Several TLR agonists have been 
approved by the food and drug administration (FDA) for use in the treatment of 
cancer patients like BCG (which activate TLR2, TLR3, TLR4, and TLR9), MPL 
(TLR4 agonist) and imiquimod (TLR7 agonist) [62]. TLR agonists should be used 
in combination with other agents to synergistically increase their immune stimula-
tory response. An important TLR modulators are summarized in Table 1 which 
having anticancer activity.
Future direction of TLRs based treatment of cancer:
In this book chapter, we summarized the role of TLRs signaling in inflammation, 
cell proliferation, apoptosis and chemo-resistance, which are the major attributes 
of cancerous cells. Beside these, several TLRs agonists and antagonists have been 
developed and/or are in clinical trials as cancer therapeutics. TLRs play a critical 
role in imparting immunity against tumor, and their antitumor effects are notice-
able as depicted from previous studies. It is quite interesting to note that activation 
of same TLR in one tumor type might induce cell death, and in a different tumor 
could exert pro-tumor effects. Using TLR agonists or antagonist as cancer thera-
peutics must be decided on the basis of TLR expression profile of tumor cells and 
resulting response within a specific cancer type [19]. The prospective approach for 
future cancer treatment will be the combination of specific TLR agonists or antago-
nists with traditional cancer treatments to improve treatment outcome. The role of 
TLRs in both promoting and inhibiting tumor growth and metastasis has been con-
firmed in various studies. However, the specific mechanism of action is still unclear 
as cancer is a multifactorial\disease, and the research of TLRs on tumor immunity 




Chloroquine TLR 7 and 9 Antagonist [50]
TAK-242 TLR 4 Antagonist [53]
IMO-3100 TLR 7, 8 and 9 Antagonist [57]
Eritoran TLR 4 Antagonist [58]
Polyriboinosinic-polyribocytidylic acid (Poly I:C) TLR 3 Agonist [16]
Calmette–Guerin strain (BCG) TLR 2, 4 and 9 Agonist [46]
Table 1. 
Different TLR modulators having anticancer activity.
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understanding of TLRs role in tumorigenesis, tumor immunity, and tumor metas-
tasis which in turn can provide new strategies and prospects for more effective 
cancer management. We anticipate that future studies on the role of TLRs in cancer 
progression and development will provide us a better insight into the mechanisms 
underplaying. Therefore, understanding the roles of TLRs in tumor biology may 
pave the way for the discovery of novel therapeutic targets in cancer therapy.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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